These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 4192759)

  • 1. [Evolution of immunoglobulins IgA, IgM, IgG and LATS during treatment of hyperthyroidism with carmibazole and radioiodine].
    Mahaux JE; Delcourt R; Nagel M; Chamla-Soumenkoff J; Levin S
    Ann Endocrinol (Paris); 1970; 31(2):314-23. PubMed ID: 4192759
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the antigen reacting with the thyroid-stimulating immunoglobulin (LATS) in thyrotoxicosis.
    Benhamou-Glynn N; el-Kabir DJ; Roitt IM; Doniach D
    Immunology; 1969 Feb; 16(2):187-204. PubMed ID: 4181510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the antibody specificity of LATS?
    Fagraeus A; Jonsson J; el-Kabir DJ
    J Clin Endocrinol Metab; 1970 Oct; 31(4):445-7. PubMed ID: 4916544
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum immunoglobulin levels in thyroid disease.
    Glynne A; Thomson JA
    Clin Exp Immunol; 1972 Sep; 12(1):71-8. PubMed ID: 4628405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
    Hardisty CA; Hanford L; Humphries H; Munro DS
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific and nonspecific responses in the bioassay of long-acting thyroid stimulator (LATS).
    Chopra IJ; Solomon DH; Limberg NP
    J Clin Endocrinol Metab; 1970 Oct; 31(4):382-90. PubMed ID: 5468701
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyperthyroidism.
    Kendall-Taylor P
    Br Med J; 1972 May; 2(5809):337-41. PubMed ID: 4112238
    [No Abstract]   [Full Text] [Related]  

  • 8. LATS-protector activity in thyrotoxicosis measured by thyroidal intracellular colloid droplet formation.
    Shishiba Y; Miyachi Y; Takaishi M; Ozawa Y
    J Clin Endocrinol Metab; 1978 May; 46(5):841-8. PubMed ID: 262769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of radioiodine and antithyroid drugs on serum long acting thyroid stimulator protector (IATS-P). A three year prospective study.
    Hardisty CA; Fowles A; Munro DS
    Clin Endocrinol (Oxf); 1984 May; 20(5):597-605. PubMed ID: 6547647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immunity and autoimmune disease.
    Roitt IM
    Vox Sang; 1969 Apr; 16(4):341-4. PubMed ID: 4184411
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunoglobulin levels and long-acting thyroid stimulator (LATS) in hyperthyroidism. A preliminary study.
    Yamakido M; Yokoyama M; Noguchi S
    Hawaii Med J; 1969; 29(2):118-9. PubMed ID: 5361480
    [No Abstract]   [Full Text] [Related]  

  • 12. The nucleic acid content of lymphocytes in thyrotoxicosis.
    Smith JF; Glen AC; Greig WR
    Clin Exp Immunol; 1971 Jun; 8(6):911-6. PubMed ID: 5104635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting thyroid stimulator (LATS) in hyperthyroidism and exophthalmos.
    Friis T
    Dan Med Bull; 1969 Nov; 16(10):294-304. PubMed ID: 5392781
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies of immune mechanisms in leprosy. II Quantitative relationships of IgG, IgA, and IgM immunoglobulins.
    Bullock WE; Ho MF; Chen MJ
    J Lab Clin Med; 1970 May; 75(5):863-70. PubMed ID: 4192266
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-acting thyroid stimulator in euthyroid relatives of thyrotoxic patients.
    Wall JR; Good BF; Hetzel BS
    Lancet; 1969 Nov; 2(7629):1024-6. PubMed ID: 4187540
    [No Abstract]   [Full Text] [Related]  

  • 16. Thyroid suppression and the long-acting thyroid stimulator following radioactive iodine therapy for thyrotoxicosis.
    Alford FP; Larkins RG; Martin FI
    Aust N Z J Med; 1971 Nov; 1(4):339-45. PubMed ID: 5292990
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chronic thrombopenic purpura. Hyperthyroidism, pretibial myxedema and L.A.T.S].
    Cattan D; Caen J; Fernandez Y; Izard J; Leclere H; Tanguy A; Lemenager J
    Presse Med (1893); 1970 Jul; 78(35):1535-40. PubMed ID: 5464336
    [No Abstract]   [Full Text] [Related]  

  • 18. [Human thyroid stimulator (HTS) in thyroid diseases].
    Hu ZY
    Zhonghua Nei Ke Za Zhi; 1984 Aug; 23(8):480-3, 525. PubMed ID: 6548953
    [No Abstract]   [Full Text] [Related]  

  • 19. [Long-acting thyroid stimulator (LATS) in thyroid gland diseases and its relationship to the thyroid gland antibodies].
    Weissbecker L; Uthgenannt H; Schemmel K; Müller W; Heesen H; Eickenbusch W; Bindeballe W
    Schweiz Med Wochenschr; 1967 Jul; 97(28):898-904. PubMed ID: 5587446
    [No Abstract]   [Full Text] [Related]  

  • 20. The prediction of relapse after drug treatment of Graves' disease by assay of long acting thyroid stimulator-protector (LATS-P).
    Hardisty CA; Hanford L; Munro DS
    Clin Endocrinol (Oxf); 1981 May; 14(5):509-17. PubMed ID: 6895487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.